Commercial thimble chambers for absorbed dose measurements at high energy electron radiation.

H. Svensson,C. Pettersson,G. Hettinger

DOI: https://doi.org/10.3109/02841867109130780

Abstract:

What problem does this paper attempt to address?

Abstract 3572: Role of the gut microbiome in androgen production and prostate cancer treatment resistance

Angelica I. Cruz Lebron,Pedro A. Balbuena-Almodóvar,Luke Mummert,Sarah Ernst,Mark Markowski,Michelle Rudek,Jason Ridlon,Karen S. Sfanos

DOI: https://doi.org/10.1158/1538-7445.am2024-3572

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Metastatic prostate cancer is often treated via a combination of androgen deprivation therapy (ADT) and the androgen receptor axis-targeted therapies abiraterone acetate + prednisone (AA/P) or enzalutamide. Unfortunately, most individuals undergoing these treatments develop resistance, termed “castration resistance”, through an unknown mechanism. Previous studies demonstrate a potential link between the gut microbiota and the treatment efficacy of endocrine therapy in metastatic castration resistant prostate cancer (mCRPC). This may be due in part to gut bacterial communities with the machinery to synthesize androgens using mechanisms distinct from human cells. For example, the bacterial desAB genes (e.g., “desmolase”) that were first described in the gut commensal bacterial species Clostridium scindens convert cortisol and prednisone to the androgenic metabolites 11β-hydroxyandrost-4-ene-3,17-dione (11OHAD) and ∆1-adrenosterone (∆1-AT), respectively. We hypothesize that androgen synthesis by the gut microbiota promotes treatment resistance to AA/P in advanced prostate cancer. This study aims to determine if androgen-converting gut bacterial species as well as circulating and fecal androgen levels correlate with AA/P treatment response in individuals with mCRPC using a combination of metagenomics and metabolomics. We further aim to demonstrate the relationship between gut bacterial androgen production and prostate cancer treatment response using an in vivo mouse model. Metagenomic sequencing showed an imbalance in microbial communities and identified the presence of androgen-synthesizing bacteria such as C. scindens in fecal samples of individuals undergoing treatment with AA/P. We also demonstrate that the relative abundance of C. scindens, as well as other species reported to generate androgens, are significantly enriched during metastatic disease progression on AA/P. Furthermore, targeted quantitative PCR of the bacterial desmolase (desA) gene demonstrated that absolute levels of desmolase are significantly higher in AA/P non-responders relative to AA/P responders, and trended higher in individuals with rising prostate-specific antigen (PSA) versus stable PSA while on AA/P. Targeted LC/MS/MS analyses of fecal samples demonstrated the presence of testosterone, dihydrotestosterone, 11OHAD, ∆1-AT, and other androgen metabolites in association with rising PSA levels in the AA/P cohort. Furthermore, we demonstrate that C. scindens converts hydrocortisone and prednisone into 11OHAD and ∆1-AT, respectively, in vitro at 48- and 72h post-treatment, which recapitulates prior published studies. Finally, we have established a prostate cancer mouse model using a VCaP xenograft in which tumor growth was significantly inhibited by abiraterone acetate in comparison to treatment with ADT alone. Additional studies will use this mouse model to study the effects of androgen metabolism by gut bacteria on AA/P efficacy. Overall, this study ascertains the ability of the human gut microbiota to harbor androgen-synthesizing bacteria, which in turn can be an alternative source of androgens that could impact the efficacy of the anti-androgen therapies used to treat metastatic prostate cancer. Citation Format: Angelica I. Cruz Lebron, Pedro A. Balbuena-Almodóvar, Luke Mummert, Sarah Ernst, Mark Markowski, Michelle Rudek, Jason Ridlon, Karen S. Sfanos. Role of the gut microbiome in androgen production and prostate cancer treatment resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3572.

oncology
Inorganic pyrophosphate-phosphohydrolytic activity in human serum. Catalytic properties of the ionic species of PPi and MgPPi complexes.

M. Hørder

DOI: https://doi.org/10.1016/0005-2744(73)90087-9

1973-09-15

Biochimica et Biophysica Acta

Abstract:
Akkermansia muciniphila Metabolite Inosine Inhibits Castration Resistance in Prostate Cancer

Yao Yu,Leqian Li,Qishen Yang,Jingwen Xue,Benlin Wang,Ming Xie,Wentai Shangguan,Zhangrui Zhu,Peng Wu

DOI: https://doi.org/10.3390/microorganisms12081653

IF: 4.5

2024-08-12

Microorganisms

Abstract:Prostate cancer (PCa) is initially sensitive to androgen deprivation therapy (ADT) but ultimately develops resistance and progresses to castration-resistant prostate cancer (CRPC) with a poor prognosis. This study indicated that some PCa patients and mice were more sensitive to ADT and entered CRPC later, which was related to the gut microbiota, especially the enrichment of Akkermansia muciniphila (AKK). Untargeted metabolomics analysis found that serum inosine level was upregulated in the treatment-sensitive group and significantly correlated with AKK. Furthermore, we revealed that intestinal permeability and serum lipopolysaccharide (LPS) levels increased in treatment-resistant mice. LPS stimulated the upregulation of p-NF-κB p65 and AR in tumors. Supplementing AKK metabolite inosine could alleviate intestinal barrier damage and reduce serum LPS level, ultimately inhibiting castration resistance via the LPS/NF-κB/AR axis. Finally, we constructed a predictive model for CRPC combining gut microbiota and clinical information (AUC = 0.729). This study revealed the potential mechanism of gut microbiota on CRPC and provided potential therapeutic targets and prognostic indicators.

microbiology
Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies

Karen S. Sfanos,Mark C. Markowski,Lauren B. Peiffer,Sarah E. Ernst,James R. White,Kenneth J. Pienta,Emmanuel S. Antonarakis,Ashley E. Ross

DOI: https://doi.org/10.1038/s41391-018-0061-x

2018-07-09

Prostate Cancer and Prostatic Diseases

Abstract:BackgroundIt is well known that the gastrointestinal (GI) microbiota can influence the metabolism, pharmacokinetics, and toxicity of cancer therapies. Conversely, the effect of cancer treatments on the composition of the GI microbiota is poorly understood. We hypothesized that oral androgen receptor axis-targeted therapies (ATT), including bicalutamide, enzalutamide, and abiraterone acetate, may be associated with compositional differences in the GI microbiota.MethodsWe profiled the fecal microbiota in a cross-sectional study of 30 patients that included healthy male volunteers and men with different clinical states of prostate cancer (i.e., localized, biochemically recurrent, and metastatic disease) using 16S rDNA amplicon sequencing. Functional inference of identified taxa was performed using PICRUSt.ResultsWe report a significant difference in alpha diversity in GI microbiota among men with versus without a prostate cancer diagnosis. Further analysis identified significant compositional differences in the GI microbiota of men taking ATT, including a greater abundance of species previously linked to response to anti-PD-1 immunotherapy such as Akkermansia muciniphila and Ruminococcaceae spp. In functional analyses, we found an enriched representation of bacterial gene pathways involved in steroid biosynthesis and steroid hormone biosynthesis in the fecal microbiota of men taking oral ATT.ConclusionsThere are measurable differences in the GI microbiota of men receiving oral ATT. We speculate that oral hormonal therapies for prostate cancer may alter the GI microbiota, influence clinical responses to ATT, and/or potentially modulate the antitumor effects of future therapies including immunotherapy. Given our findings, larger, longitudinal studies are warranted.

oncology,urology & nephrology
Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer

Emmanuel Chamorey,Marc Pujalte-Martin,Jean-Marc Ferrero,Hakim Mahammedi,Gwenaelle Gravis,Guilhem Roubaud,Philippe Beuzeboc,Remy Largillier,Delphine Borchiellini,Claude Linassier,Hélène Bouges,Marie-Christine Etienne-Grimaldi,Renaud Schiappa,Jocelyn Gal,Gérard Milano

DOI: https://doi.org/10.3390/ijms25116058

IF: 5.6

2024-05-31

International Journal of Molecular Sciences

Abstract:This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that individual AA concentrations remained constant over treatment time, with no noticeable changes during repeated long-term drug administration for up to 120 days. There was no correlation between AA concentrations and survival outcomes. However, a significant association between higher AA concentrations and better clinical benefit was observed (p = 0.041). The safety data did not correlate with the AA PK data. A significant positive correlation (r = 0.40, p < 0.001) was observed between mean AA concentration and patient age: the older the patient, the higher the AA concentration. Patient age was found to impact steady-state AA concentration: the older the patient, the higher the mean AA concentration. Altogether, these data may help to guide future research and clinical trials in order to maximize the benefits of AA metastatic castration-resistant prostate cancer patients.

biochemistry & molecular biology,chemistry, multidisciplinary
Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells

Wenting Pan,Zhouwei Zhang,Hannah Kimball,Fangfang Qu,Kyler Berlind,Konrad H. Stopsack,Gwo-Shu Mary Lee,Toni K. Choueiri,Philip W. Kantoff

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4391

IF: 13.801

2021-04-01

Clinical Cancer Research

Abstract:Purpose: Abiraterone acetate (AA), an inhibitor of cytochrome P450 17alpha-hydroxylase/17, 20 lyase, is an FDA-approved drug for advanced prostate cancer. However, not all patients respond to AA, and AA resistance ultimately develops in patients who initially respond. We aimed to identify AA resistance mechanisms in prostate cancer cells. Experimental Design: We established several AA-resistant cell lines and performed a comprehensive study on mechanisms involved in AA resistance development. RNA sequencing and phospho-kinase array screenings were performed to discover that the cAMP-response element CRE binding protein 1 (CREB1) was a critical molecule in AA resistance development. Results: The drug-resistant cell lines are phenotypically stable without drug selection, and exhibit permanent global gene expression changes. The phosphorylated CREB1 (pCREB1) is increased in AA-resistant cell lines and is critical in controlling global gene expression. Upregulation of pCREB1 desensitized prostate cancer cells to AA, while blocking CREB1 phosphorylation resensitized AA-resistant cells to AA. AA treatment increases intracellular cyclic AMP (cAMP) levels, induces kinases activity, and leads to the phosphorylation of CREB1, which may subsequently augment the essential role of the CBP/p300 complex in AA-resistant cells because AA-resistant cells exhibit a relatively higher sensitivity to CBP/p300 inhibitors. Further pharmacokinetics studies demonstrated that AA significantly synergizes with CBP/p300 inhibitors in limiting the growth of prostate cancer cells. Conclusions: Our studies suggest that AA treatment upregulates pCREB1, which enhances CBP/p300 activity, leading to global gene expression alterations, subsequently resulting in drug resistance development. Combining AA with therapies targeting resistance mechanisms may provide a more effective treatment strategy.

oncology
Assessment of Abiraterone (abi) Tumor Cell Activity Via in Vitro Models of Androgen (A)-Responsive Prostate Cancer

Ian Hickson,Ann Marien,Maarten Derks,Marc Janssen

DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.e15166

IF: 45.3

2012-01-01

Journal of Clinical Oncology

Abstract:e15166 Background: Inhibition of CYP17 by abiraterone acetate (AA) blocks A biosynthesis, reduces A levels and results in inhibition of A-dependent tumor growth. AA has been shown to improve survival in patients with metastatic castrate-resistant prostate cancer (HR = 0.74) (Scher, ASCO 2011). AA is converted to ABI in vivo. This study investigates whether direct effects of ABI on tumor cells (ie, blockade of intratumoral A synthesis) may contribute to the clinical efficacy of AA using in vitro models. Methods: LNCaP cells (human prostate cancer cell line [HPCCL]) were grown in 2D and 3D cultures, and ABI activity was assessed by reduction of androgen receptor (AR) output in gene expression profiling (Affymetrix microarray), reporter assay, and by immunoblot for A-responsive signals. Using ABI-sensitive LNCaP cells, responses were further characterized in the presence or absence of ligand (dihydrotestosterone [DHT]) and with A-targeting agents TOK-001 and MDV3100. Results: ABI exposure resulted in dose-dependent modulation of A-dependent gene expression in Affymetrix microarray analysis of 2D and 3D cultures. Similar results were seen in an analysis of AR-dependent protein and in an AR-driven reporter assay in 2D LNCaP or VCaP (another HPCCL) cell culture. In LNCaP, AR output was inhibited by low concentrations of ABI (IC50 100-300 nM), comparable to TOK-001 (IC50 30-100 nM) and less potent than MDV3100 (IC50 10-30 nM). Growth inhibition (MTT assay) occurred at concentrations 10-fold higher for all compounds. For ABI and TOK-001, inhibition of AR output was reduced by DHT (30- to 100-fold increase in IC50); with MDV3100, the shift in IC50 was less (10-fold) with agonism of AR output at low nM concentrations. Conclusions: ABI has an inhibitory effect on AR output in LNCaP cells. Partially overcoming this inhibition through addition of DHT implies that CYP17 inhibition and the subsequent A reduction play a role in the intratumoral activity of AA. However, persistent inhibition of AR output in the presence of DHT implies additional anti-A effects of AA in prostate tumor cells. This model may provide a useful tool for the study of AR-targeted therapies, combinations of agents, and resistance to agents targeting A.
Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer

Yufei Liu,Haowen Jiang

DOI: https://doi.org/10.21037/tau-20-566

2020-10-01

Translational Andrology and Urology

Abstract:BACKGROUND: It is known that gut microbiota can regulate cancer therapies. We hypothesized that gut microbiota may interact with androgen deprivation therapy (ADT) in the process of castration-resistant prostate cancer (CRPC). Here, the differences in gut microbiota between matched hormone-sensitive prostate cancer (HSPC) and CRPC were determined before and after ADT.METHODS: We profiled the fecal microbiota in matched HSPC and CRPC from 21 patients who received ADT at our urological center using 16S rRNA gene amplicon sequencing. Differences in microbiota were determined with α/β-diversity and LefSe analysis. Functional inference of microbiota was performed with PICRUSt.RESULTS: The results showed that the gut microbial community in CRPC was significantly altered with increased abundance of several bacterial flora including genus Phascolarctobacterium and Ruminococcus. For functional analyses, bacterial gene pathways involved in terpenoids/polyketides metabolism and ether lipid metabolism were significantly activated in CRPC.CONCLUSIONS: Measurable differences in the gut microbiota were identified between HSPC and CRPC. Functional validations are further needed to ascertain the underlying mechanism of these differential microbiota in the process of CRPC, and their potential as new targets to enhance ADT responses.

urology & nephrology,andrology
Abstract LB-248: Investigation of tumor cell activity of Abiraterone usinginvitromodel systems of androgen (A)-responsive prostate cancer

Ann Marien,Maarten Derks,Marc Janssen,Ian Hickson

DOI: https://doi.org/10.1158/1538-7445.am2012-lb-248

2012-01-01

Abstract:Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Objective Abiraterone acetate (AA) has recently been approved for the treatment of metastatic castration-resistant prostate cancer. Clinical activity of AA has been demonstrated and is due to systemic reduction of A levels by inhibition of cytochrome P450 c17 (CYP17) activity. AA is converted to abiraterone (ABI) in vivo. We hypothesized that a direct effect of ABI on tumor cells also contributes to its antitumor activity. Utilizing LNCaP cells (human prostate cancer cell line [HPCCL]), the effects of ABI were compared in standard 2D and more complex 3D tumor cell cultures to explore tumor microenvironment factors (eg, stromal CYP17 activity). Methods Androgen receptor (AR) output was studied by Western blot, luciferase reporter assay, and Affymetrix® microarrays using ABI. By continued growth of LNCaP cells in defined calf serum, we have identified a culture-derived line that is sensitive to ABI inhibition in vitro, both in 2D and 3D cultures. These cells were used to study ABI inhibition of tumor cells in the presence or absence of ligand (dihydrotestosterone [DHT]) and with reference to other molecules targeting the A axis (MDV3100 and TOK-001). Results ABI exposure resulted in a dose-dependent modulation of expression of A-dependent genes in Affymetrix microarray analysis of 2D and 3D cultures. Further analyses using 2D cultures only, at the level of AR-dependent protein modulation (eg, kallikreins [KLKs]), and an AR-driven luciferase reporter assay revealed that AR output was inhibited by concentrations of ABI as low as 10 nM (IC50 100-300 nM), comparable with inhibition by TOK-001 (IC50 30-100 nM). The potency of MDV3100 was greater (IC50 10-30 nM). Growth inhibition, as assessed by MTT assay, occurred at concentrations ∼1 log higher for all compounds. To address the role of CYP17 inhibition, studies were conducted in the presence of DHT; IC50 for ABI increased (IC50 3-10 uM), but inhibition of AR output was still detected at the gene, reporter, and protein levels; similar results were seen with TOK-001. The shift in inhibition with MDV3100 was less (10-fold), but with apparent agonism at low nM concentrations. Similar data were also obtained in VCaP cells (another HPCCL), excluding a role for mutant AR in the observed response. Conclusions ABI has an inhibitory effect on AR output of prostate tumor cells at nM concentrations. Inhibition was partially overcome by addition of DHT, indicating that CYP17 inhibition and subsequent A reduction contribute to the intratumoral activity of AA. However, it appears that inhibition of AR output persists in the presence of DHT, implying that AA may exert additional anti-A effects in the prostate tumor cell. We are characterizing the LNCaP model further as a tool for rapid evaluation of: additional therapies targeting ARs, combinations of agents, and potential mechanisms of resistance to A-targeted therapies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-248. doi:1538-7445.AM2012-LB-248
The prognostic value of ductal adenocarcinoma of the prostate in patients with advanced prostate cancer treated with abiraterone acetate.

Yifu Shi,Xinyuan Wei,Fengnian Zhao,Jinge Zhao,Pengfei Shen,Ni Chen,Hao Zeng

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.167

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:167 Background: Previous studies have indicated that ductal adenocarcinoma of the prostate (DA) is associated with adverse prognosis in patients with localized prostate cancer (PCa). However, the clinical significance of DA in advanced PCa remains largely ambiguous. This study endeavors to investigate the relationship between the existence of DA in prostate biopsy specimens and treatment outcomes among patients with advanced PCa receiving abiraterone acetate (AA) therapy. Methods: We retrospectively analyzed data from 440 patients with advanced PCa who received AA at either the metastatic hormone-sensitive (mHSPC, N=123) or castration-resistant PCa (mCRPC, N=317) stage. The presence of DA and its proportion was evaluated based on prostate biopsy specimens. Kaplan-Meier curves and COX regression were used to evaluate the predictive significance of DA on AA efficacy, including PSA response, PSA progression-free survival (PSA-PFS), and radiographic progression-free survival (rPFS). Results: In aggregate, DA was detected in 35/440 (8.0%) patients, with 13/440 (3.0%) and 22/440 (5.0%) men harboring DA<5% and ≥5%, respectively, in the total tumors. The overall PSA response rate in the entire cohort was 302/440 (68.6%), and it was comparable for people with and without DA, with both groups having a response rate of 68.6%. Of note, compared with patients without DA, men with DA have significantly longer median PSA-PFS (mPSA-PFS, 12.1- vs. 25.0-Mo, P=0.005) and median rPFS (mrPFS, 19.8 vs. 38.2-Mo, P=0.034). Subgroup analysis based on DA proportion further revealed that in comparison with PCa without DA, DA≥5% was an indicator of favorable PSA-PFS (HR, 95%CI: 0.28, 0.14-0.56, p<0.001) and rPFS (HR, 95%CI: 0.35, 0.18-0.72, p=0.004), while DA<5% was not. In multivariate COX regression analysis, after adjusting by clinicopathological factors, including mCRPC/mHSPC stage, ISUP grading, metastatic burden, pain score and pretreatment hemoglobin, alkaline phosphatase, and lactate dehydrogenase, DA≥5% was still independently associated with better therapeutic efficacy of AA treatment (PSA-PFS: HR, 95%CI: 0.36, 0.17-0.74, p<0.001; rPFS: HR, 95%CI: 0.47, 0.23-0.96, p=0.040). Conclusions: A DA proportion ≥5% in the tumor is related to improved treatment efficacy for individuals with advanced PCa receiving AA. Thus, in the pathological diagnosis of PCa, it is necessary to routinely report the presence and proportion of DA in order to aid with treatment decision-making.

oncology
Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy

Safae Terrisse,Laurence Zitvogel,Guido Kroemer

DOI: https://doi.org/10.15698/mic2022.12.787

2022-12-05

Microbial Cell

Abstract:Prostate cancer (PC) can be kept in check by androgen deprivation therapy (ADT, usually with the androgen synthesis inhibitor abiraterone acetate or the androgen receptor antagonist such as enzalutamide) until the tumor evolves to castration-resistant prostate cancer (CRPC). The transition of hormone-sensitive PC (HSPC) to CPRC has been explained by cancer cell-intrinsic resistance mechanisms. Recent data indicate that this transition is also marked by cancer cell-extrinsic mechanisms such as the failure of ADT-induced PC immunosurveillance, which depends on the presence of immunostimulatory bacteria in the gut. Moreover, intestinal bacteria that degrade drugs used for ADT, as well as bacteria that produce androgens, can interfere with the efficacy of ADT. Thus, specific bacteria in the gut serve as a source of testosterone, which accelerates prostate cancer progression, and men with CRPC exhibit an increased abundance of such bacteria with androgenic functions. In conclusion, the response of PC to ADT is profoundly influenced by the composition of the microbiota with its immunostimulatory, immunosuppressive and directly ADT-subversive elements.
The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2

Marzieh Ehsani,Sophie Bartsch,Seyed Mohammad Mahdi Rasa,Jessica Dittmann,Thanakorn Pungsrinont,Laura Neubert,Soeren S. Huettner,Roland Kotolloshi,Katrin Schindler,Aya Ahmad,Alexander S. Mosig,Lisa Adam,Alessandro Ori,Francesco Neri,Alexander Berndt,Marc-Oliver Grimm,Aria Baniahmad

DOI: https://doi.org/10.1038/s41388-022-02333-7

IF: 8.756

2022-05-06

Oncogene

Abstract:Castration-resistant prostate cancer (CRPC) is an aggressive lethal form of prostate cancer (PCa). Atraric acid (AA) not only inhibits the wild-type androgen receptor (AR) but also those AR mutants that confer therapy resistance to other clinically used AR antagonists, indicating a different mode of AR antagonism. AA induces cellular senescence and inhibits CRPC tumour growth in in vivo xenograft mouse model associated with reduced neo-angiogenesis suggesting the repression of intratumoural neo-angiogenesis by AA. In line with this, the secretome of CRPC cells mediates neo-angiogenesis in an androgen-dependent manner, which is counteracted by AA. This was confirmed by two in vitro models using primary human endothelial cells. Transcriptome sequencing revealed upregulated angiogenic pathways by androgen, being however VEGF-independent, and pointing to the pro-angiogenic factor angiopoietin 2 (ANGPT2) as a key driver of neo-angiogenesis induced by androgens and repressed by AA. In agreement with this, AA treatment of native patient-derived PCa tumour samples ex vivo inhibits ANGPT2 expression. Mechanistically, in addition to AA, immune-depletion of ANGPT2 from secretome or blocking ANGPT2-receptors inhibits androgen-induced angiogenesis. Taken together, we reveal a VEGF-independent ANGPT2-mediated angiogenic pathway that is inhibited by AA leading to repression of androgen-regulated neo-angiogenesis.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Abstract 6670: Could immunotherapy offer potential in managing bacterial dysbiosis in prostate cancer

Tim Oliver,Belinda Nedjai,Emily Lane,Frank Chinegwundoh,Prabhakar Rajan,Jack Cuzick

DOI: https://doi.org/10.1158/1538-7445.am2024-6670

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Background: Since 2006 three studies, involving 289,089 adolescents, demonstrated a significant association (1.67(0.79-3.55),1.7(1.03-2.70),2.37(1.19-4.73)) between pubertal acne and poor outcome prostate cancer(PC) 30+ years later. This suggested Cutibacterium acnes, amicroaerophylic bacterium, might be contributing to PC bacterial dysbiosis analogous to the role of H. pylori in stomach cancer and explain why circumcision reduces PC risk. Six years ago, using MALDI-TOF, we demonstrated that the presence of seven obligate anaerobe species in addition to C. acnes were increased in PC and linked to increased PSA. This presentation studies stored samples from the PROVENT chemoprevention randomised PC active surveillance phase 2 trial analysed using 16S rDNA sequencing, and comparing obligate anaerobe frequency with those detected by culture and MALDI-TOF identification and their influence on PSA expression. Methods: 89 urines of PROVENT trial patients were studied using 16S rDNA sequencing and followed for 24 months. In addition, 39 previously reported MALDI-TOF screened cohort patients (21 PCs and 18 BPHs) followed for 43 months. The frequency of 7 obligate bacterial genera (Actinobaculum, Finegoldia, Prevotella, Peptoniphilus, Peptostreptococcus & Viellonella) was studied. Results: Twenty six of 89 (29%) PROVENT urine samples had a majority of bacteria detected as obligate anaerobes (mean=68%), while it was 12 of the 39 (31%) in PC tested in MALDI-TOF. In the combined series, those patients (n=38) with obligate anaerobes had mean PSA of 9.59 ug/L, while those without obligate anaerobes had a mean PSA of 6.29 ug/L (n=90), (t=-2.925, p = 0.0058). In the MALDI-TOF series, statistically increased urological intervention rate was associated with the presence of anaerobes (p=0.045, Fisher’s exact test). Discussion: These findings suggest that obligate anaerobe bacterial dysbiosis could be contributing to raised PSA through prostate cell damage, and possibly participating in the chronic inflammation and hypervascular changes that are seen in precancerous lesions. Checkpoint inhibitors have shown little benefit in prostate cancer. Recent reports from animal model studies of BCG resistance have suggested a short course combination of anti PDLI and anti NKG2a could break immune tolerance associated with expression of HLA-E and this approach could be of use to break tolerance to bacterial dysbiosis in the future. Citation Format: Tim Oliver, Belinda Nedjai, Emily Lane, Frank Chinegwundoh, Prabhakar Rajan, Jack Cuzick. Could immunotherapy offer potential in managing bacterial dysbiosis in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6670.

oncology
Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China

Min Liu,Jiaqing Yan,Kaidi Le,Ying Li,Nianzeng Xing,Guohui Li

DOI: https://doi.org/10.3389/fendo.2023.1158949

2023-05-12

Abstract:Background: This research work was aimed at evaluating the incidence and risk factors of adverse events (AEs) occurring in patients treated with abiraterone acetate (AA) and prednisone (PDN) outside clinical trials. These associations were assessed regarding the survival outcomes. Methods: The study included 191 patients aged ≥18 years of confirmed metastatic castration-resistant prostate cancer (mCRPC) between March 2017 and April 2022. AE incidences were descriptively summarized from the whole cohort. Baseline characteristics, safety (treatment-emergent AEs and severe AEs), and efficacy [progression-free survival (PFS)] were analyzed. Multi-variable Cox proportional hazards models were employed to assess the factors linked with PFS. Results: Overall, the median PFS was 17.16 months (range, 0.5-57.58). Patient baseline prostate-specific antigen (PSA) ≧̸10 ng/ml (p = 0.000), multiple organ metastasis (p = 0.007), hypertension (p = 0.004), and coronary heart disease (p = 0.004) were associated with worse PFS; however, radiotherapy (p = 0.028) was linked to better PFS at univariate analysis in the overall cohort. Baseline multiple organ metastasis, hypertension, and radiotherapy remained statistically significant in multivariable models (p = 0.007, p= 0.005, and p = 0.011, respectively).Incidence of AEs showed increased bilirubin (BIL) (55/191 patients, 28.8%) followed by increased alanine aminotransferase/aspartate aminotransferase (ALT/AST) (48/191 patients, 25.09%). The most common grade 3 AEs were increased ALT (3/191, 1.57%) followed by elevated BIL, hypercholesterolemia, and hypokalemia. Anemia had shorter PFS. There were no unexpected AEs in any patient. Conclusion: AA is effective and tolerated in asymptomatic or slightly symptomatic mCRPC in "real-life" setting. The survival outcomes are influenced by multiple organ metastasis, hypertension, and radiotherapy.
An expanded metabolic pathway for androgen production by host-associated bacteria

Taojun Wang,Saeed Ahmad,Angélica Cruz-Lebrón,Sarah E. Ernst,Kelly Yovani Olivos Caicedo,Yoon Jeong,Briawna Binion,Pauline Mbuvi,Debapriya Dutta,Francelys V. Fernandez-Materan,Adam M. Breister,Jae Won Lee,Jason D. Kang,Spencer C. Harris,Shigeo Ikegawa,H. Rex Gaskins,John W. Erdman Jr.,Glen Yang,Isaac Cann,Steven L. Daniel,Phillip B. Hylemon,Karthik Anantharaman,Rafael C. Bernardi,João M.P. Alves,Karen S. Sfanos,Joseph Irudayaraj,Jason M. Ridlon

DOI: https://doi.org/10.1101/2024.06.09.598130

2024-06-09

Abstract:A growing body of literature implicates host-associated microbiota in the modulation of circulating androgen levels in the host, which could have far-reaching implications for androgen-mediated diseases. However, the microbial genetic pathways involved in androgen production remain unknown. Here, we report the first host-associated microbial gene (desF) encoding an enzyme that catalyzes conversion of androstenedione to epitestosterone (epiT) in the gut bacterium, Clostridium scindens. Despite current dogma that epiT is a nuclear androgen-receptor (AR) antagonist, we demonstrate that epiT is a potent androgen, as assessed by its ability to promote prostate cancer cell growth and expression of prostate specific antigen (PSA). We then quantified the desF gene in fecal samples collected from individuals with advanced prostate cancer (rising blood PSA) undergoing androgen deprivation therapy combined with abiraterone acetate and prednisone (AA/P). Strikingly, fecal desF levels were elevated in a subset of individuals progressing on AA/P versus samples taken during AA/P response (stable). Importantly, we observed that AA does not inhibit the bacterial desmolase enzyme that is analogous to the human drug target of AA. We then determined that bacterial isolates from urine or prostatectomy tissue are capable of androgen production. From these isolates we detected 17β-hydroxysteroid dehydrogenase (17β-HSDH) activity, which has not been previously reported in urinary tract bacteria, and discovered the desG gene in urinary isolates encoding 17β-HSDH that catalyzed conversion of androstenedione to testosterone. Applying advanced artificial intelligence and molecular dynamics, we predict the structures and ligand binding to DesF and DesG. Using a novel bioengineered microencapsulation technique, we demonstrate that urinary androgen-producing bacterial strains can also promote prostate cancer cell growth through steroid metabolism. Taken together, our results are a significant advance for steroid microbiology in humans and suggest that these microbial biotransformations should be further studied in the context of androgen-mediated physiological processes and diseases.

Microbiology
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

J O'Shaughnessy,M Campone,E Brain,P Neven,D Hayes,I Bondarenko,T W Griffin,J Martin,P De Porre,T Kheoh,M K Yu,W Peng,S Johnston

DOI: https://doi.org/10.1093/annonc/mdv487

Abstract:Background: Androgen receptor (AR) signaling and incomplete inhibition of estrogen signaling may contribute to metastatic breast cancer (MBC) resistance to a nonsteroidal aromatase inhibitor (NSAI; letrozole or anastrozole). We assessed whether combined inhibition of androgen biosynthesis with abiraterone acetate plus prednisone and estradiol synthesis with exemestane (E) may be of clinical benefit to postmenopausal patients with NSAI-pretreated estrogen receptor-positive (ER+) MBC. Patients and methods: Patients (N = 297) were stratified by the number of prior therapies for metastatic disease (0-1 versus 2) and by prior NSAI use (adjuvant versus metastatic), and randomized (1 : 1 : 1) to receive oral once daily 1000 mg abiraterone acetate plus 5 mg prednisone (AA) versus AA with 25 mg E (AAE) versus 25 mg E alone (E). Each treatment arm was well balanced with regard to the proportion of patients with AR-positive breast cancer. The primary end point was progression-free survival (PFS). Secondary end points included overall survival, clinical benefit rate, duration of response, and overall response rate. Results: There was no significant difference in PFS with AA versus E (3.7 versus 3.7 months; hazard ratio [HR] = 1.1; 95% confidence interval [CI] 0.82-1.60; P = 0.437) or AAE versus E (4.5 versus 3.7 months; HR = 0.96; 95% CI 0.70-1.32; P = 0.794). Increased serum progesterone concentrations were observed in both arms receiving AA, but not with E. Grade 3 or 4 treatment-emergent adverse events associated with AA, including hypokalemia and hypertension, were less common in patients in the E (2.0% and 2.9%, respectively) and AA arms (3.4% and 1.1%, respectively) than in the AAE arm (5.8% for both). Conclusions: Adding AA to E in NSAI-pretreated ER+ MBC patients did not improve PFS compared with treatment with E. An AA-induced progesterone increase may have contributed to this lack of clinical activity. Clinicaltrialsgov: NCT01381874.
Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer

Jürgen E Gschwend,Kurt Miller

DOI: https://doi.org/10.1080/23808993.2021.1863781

2020-12-23

Expert Review of Precision Medicine and Drug Development

Abstract:Introduction: New-generation hormonal therapies such as abiraterone acetate (AA) in combination with prednisone or prednisolone (AAP) have improved the overall survival (OS) in patients with chemotherapy-pretreated and naïve metastatic castration-resistant prostate cancer (mCRPC). More recently, AAP has demonstrated efficacy in newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and has received expanded approval for this indication. Areas covered: This review is intended to provide a thorough overview of AA as the first-in-class and only currently approved steroid 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor for prostate cancer. To the best of our knowledge, this is the most comprehensive review of AAP that covers all three indications: mCRPC in the pre- and post-chemotherapy setting, and mHSPC. We describe, among other things, the mechanism of action of AA and review data on its efficacy and safety from phase 1, 2 and the pivotal phase 3 clinical trials that support its use in the mentioned approved indications. Expert opinion: AAP has been established over the past 10 years and was added to the WHO list of essential medicines in 2019 through an evidence-based selection process in which quality, safety, efficacy, and cost-effectiveness are key criteria, highlighting its role in the current therapeutic landscape of prostate cancer management.

English Else
Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

Safae Terrisse,Anne-Gaelle Goubet,Kousuke Ueda,Andrew Maltez Thomas,Valentin Quiniou,Cassandra Thelemaque,Garett Dunsmore,Emmanuel Clave,Melissa Gamat-Huber,Satoru Yonekura,Gladys Ferrere,Conrad Rauber,Hang Phuong Pham,Jean-Eudes Fahrner,Eugenie Pizzato,Pierre Ly,Marine Fidelle,Marine Mazzenga,Carolina Alves Costa Silva,Federica Armanini,Federica Pinto,Francesco Asnicar,Romain Daillère,Lisa Derosa,Corentin Richard,Pierre Blanchard,Bertrand Routy,Stéphane Culine,Paule Opolon,Aymeric Silvin,Florent Ginhoux,Antoine Toubert,Nicola Segata,Douglas G McNeel,Karim Fizazi,Guido Kroemer,Laurence Zitvogel

DOI: https://doi.org/10.1136/jitc-2021-004191

IF: 12.469

2022-03-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant PC (CRPC). We investigated a mouse model of PC as well as specimens from PC patients to unravel an unsuspected contribution of thymus-derived T lymphocytes and the intestinal microbiota in the efficacy of ADT. Methods Preclinical experiments were performed in PC-bearing mice, immunocompetent or immunodeficient. In parallel, we prospectively included 65 HSPC and CRPC patients (Oncobiotic trial) to analyze their feces and blood specimens. Results In PC-bearing mice, ADT increased thymic cellularity and output. PC implanted in T lymphocyte-depleted or athymic mice responded less efficiently to ADT than in immunocompetent mice. Moreover, depletion of the intestinal microbiota by oral antibiotics reduced the efficacy of ADT. PC reduced the relative abundance of Akkermansia muciniphila in the gut, and this effect was reversed by ADT. Moreover, cohousing of PC-bearing mice with tumor-free mice or oral gavage with Akkermansia improved the efficacy of ADT. This appears to be applicable to PC patients because long-term ADT resulted in an increase of thymic output, as demonstrated by an increase in circulating recent thymic emigrant cells (sjTRECs). Moreover, as compared with HSPC controls, CRPC patients demonstrated a shift in their intestinal microbiota that significantly correlated with sjTRECs. While feces from healthy volunteers restored ADT efficacy, feces from PC patients failed to do so. Conclusions These findings suggest the potential clinical utility of reversing intestinal dysbiosis and repairing acquired immune defects in PC patients.

oncology,immunology
Anti-prostate cancer metabolites from the soil-derived Aspergillus neoniveus

Menna Fayek,Hassan Y Ebrahim,Heba E Elsayed,Mohamed S Abdel-Aziz,Benson M Kariuki,Fatma A Moharram

DOI: https://doi.org/10.3389/fphar.2022.1006062

2022-10-14

Abstract:Prostate cancer (PCa) ranks as one of the most commonly diagnosed malignancies worldwide. Toxicity, lack of clinical efficacy, and development of resistance phenotypes are the main challenges in the control of prostate malignancies. Notably, castration-resistance prostate cancer (CRPCa) is a highly aggressive and metastatic phenotype of the disease with a poor prognosis and very limited therapeutic options. Herein, we report the isolation and genotypic identification of a soil-derived fungus Aspergillus neoniveus using the PCR-based internal transcribed spacer (ITS) region amplification approach. HPLC/MS investigation of the metabolic profile of the ethyl acetate extract from the fungal biomass revealed tentative identification of forty-five compounds belonging to various chemical classes including γ-butyrolactones, alkaloids, phenolics, and quinoids. Furthermore, the chromatographic purification of microbial extract enabled the identification of nervonic acid methyl ester (1) for the first time from endophytic fungi, as well as acetyl aszonalenin (2), and butyrolactone II (3) for the first time from A. neoniveus. The chemical frameworks of the isolated compounds were identified via extensive spectral analysis including 1 and 2D NMR and MS. The X-ray crystal structure and absolute configuration of acetyl aszonalenin (2) were also determined. Additionally, screening of in vitro anticancer activity of the fungal extract revealed its potential antiproliferative and anti-migratory activities against five different prostate cancer cells (PC3, PC-3M, DU-145, CWR-R1ca, and 22Rv1), including different cells with the castration-resistance phenotype. Moreover, the isolated metabolites significantly inhibited the proliferation, migration, and colonization of human prostate cancer cells at low micromolar levels, thus providing credence for future investigation of these metabolites in relevant anti-prostate cancer animal models. Furthermore, computational target prediction tools identified the cannabinoid G-protein coupled receptors type 1 (CB1) as a potential biological target mediating, at least in part, the anticancer effects of acetylaszonalenin (2). Moreover, molecular modeling and docking studies revealed a favorable binding pose at the CB1 receptor orthosteric ligand pocket aided by multiple polar and hydrophobic interactions with critical amino acids. In conclusion, the Aspergillus neoniveus-derived prenylated indole alkaloid acetylaszonalenin has promising anticancer activity and is amenable to further hit-to-lead optimization for the control of prostate malignancies via modulating CB1 receptors.
Abstract 4975: Anti-cancer effect of a probiotic bacteria-derived compound, 1,4-Dihydroxy-2-naphthoic acid in prostate cancer

Shreeja Srinivas Bitla,Gnanasekar Munirathinam

DOI: https://doi.org/10.1158/1538-7445.am2023-4975

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Cancer incidence has been increasing globally and the major cause for mortality associated with this disease is due to metastasis development. Followed by skin and lung cancer, prostate cancer (PCa) is one of the most common cancers prevailing among older men in the United States. Although androgen deprivation therapy (ADT) is the mainstay treatment for PCa, most patients undergoing ADT eventually develop metastatic PCa. Moreover, other treatment options, such as chemotherapy and radiotherapy, have toxic side effects and are ineffective in controlling advanced PCa. Hence, there arises a need for identifying alternative agents with possibly fewer side effects. The gut biome plays a significant role in regulating many bodily functions like digestion, immunity, and including cancer prevention. Probiotics, commonly known as 'good bacteria,' are living microorganisms that provide health promoting benefits. A probiotic metabolite, 1,4-Dihydroxy-2-naphthoic acid (DHNA), is an anti-inflammatory aryl hydrocarbon receptor (Ahr) agonist which is yet to be explored for its anticancer activity. Inhibiting the inflammatory signaling axis and activating Ahr by DHNA could be a promising strategy to counteract metastatic PCa. Cell viability assays revealed that 1,4-DHNA is highly toxic in metastatic prostate cancer cell lines such as DU145 and PC3 compared to normal prostate epithelial cells like RWPE-1 and human prostate stromal myofibroblast cell line, WPMY-1, with an approximate IC50 value of 5 μM in DU145 and PC3 and about 20 μM and 75 μM in WPMY-1 and RWPE-1 respectively. DHNA reduced the colony forming abilities of BPH-Cd, PC3, and DU145 in clonogenic assay and suppressed the BPH-Cd spheroid growth in spheroid formation assay, revealing its anti-tumorigenic potential. Trans-well migration assay using BPH-Cd, PC3, and DU145 showed a decrease in cell migration, hinting at the drug's anti-metastatic ability. G2/M phase arrest in cell cycle analysis and dose-dependent increase in apoptosis of DHNA-treated DU145, PC3, and LNCaP cell lines reiterated its anti-cancer potential. Western blot results in PC3 and DU145 showed significant dose-dependent inhibition of protooncogene β-catenin expression. Downregulation of cell cycle proteins like cyclin D1 and increased expression of effector caspase, cleaved caspase 7 support cell death promoting effects of DHNA via an intrinsic apoptotic pathway. Our pre-clinical data suggest that DHNA can be a potential drug for inhibiting both prostate tumor growth and metastasis. Further research is warranted to ascertain the anti-metastatic and underlying anti-cancer mechanisms to help translate the findings to clinical use. Citation Format: Shreeja Srinivas Bitla, Gnanasekar Munirathinam. Anti-cancer effect of a probiotic bacteria-derived compound, 1,4-Dihydroxy-2-naphthoic acid in prostate cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4975.

oncology

Commercial thimble chambers for absorbed dose measurements at high energy electron radiation.

Abstract 3572: Role of the gut microbiome in androgen production and prostate cancer treatment resistance

Inorganic pyrophosphate-phosphohydrolytic activity in human serum. Catalytic properties of the ionic species of PPi and MgPPi complexes.

Akkermansia muciniphila Metabolite Inosine Inhibits Castration Resistance in Prostate Cancer

Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies

Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer

Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells

Assessment of Abiraterone (abi) Tumor Cell Activity Via in Vitro Models of Androgen (A)-Responsive Prostate Cancer

Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer

Abstract LB-248: Investigation of tumor cell activity of Abiraterone usinginvitromodel systems of androgen (A)-responsive prostate cancer

The prognostic value of ductal adenocarcinoma of the prostate in patients with advanced prostate cancer treated with abiraterone acetate.

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy

The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2

Abstract 6670: Could immunotherapy offer potential in managing bacterial dysbiosis in prostate cancer

Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China

An expanded metabolic pathway for androgen production by host-associated bacteria

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

Anti-prostate cancer metabolites from the soil-derived Aspergillus neoniveus

Abstract 4975: Anti-cancer effect of a probiotic bacteria-derived compound, 1,4-Dihydroxy-2-naphthoic acid in prostate cancer